NCT02144168

Brief Summary

Primary objective of this study is to measure the change of concentration of faecal bifidobacteria between critically ill patients who receive enteral formula with and without prebiotics during enteral nutrition.Our null hypothesis is that there is no difference in the concentration of faecal bifidobacteria between critically ill patients who receive enteral formula with and without prebiotics during enteral nutrition (EN). Three faecal samples will be taken from the patient. First faecal sample is the first stool after initiation of EN and second sample is taken seven days after the initial sample and the third faecal sample is taken at day 14 after initial sample. Patient will be randomized to receive either of described formula after baseline (first) stool sample is obtained. Patient will be monitored up to 14 days after the initial stool sample is obtained.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2014

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 19, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 21, 2014

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2014

Completed
Last Updated

May 21, 2014

Status Verified

May 1, 2014

Enrollment Period

8 months

First QC Date

May 19, 2014

Last Update Submit

May 19, 2014

Conditions

Keywords

PrebioticsdiarrhoeaEnteral nutritionFibreBifidobacteriaSCFA

Outcome Measures

Primary Outcomes (1)

  • Incidence of diarrhoea

    up to 14 days post intervention

Secondary Outcomes (1)

  • Changes in faecal microbiota

    baseline, 1 week & 2 weeks after baseline sample

Other Outcomes (1)

  • Changes in short chain fatty acid

    baseline, 1 week & 2 weeks after baseline sample

Study Arms (2)

prebiotics-free enteral formula

ACTIVE COMPARATOR

Patients in this arm will be receiving standard, prebiotics-free enteral formula : Osmolite 1 cal

Dietary Supplement: Prebiotics-free enteral formula

prebiotics containing enteral formula

EXPERIMENTAL

Patients in this arm will be receiving prebiotics containing enteral formula:Ensure Fos for 14 days

Dietary Supplement: Prebiotics containing enteral formula

Interventions

Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained

Also known as: Osmolite 1 cal
prebiotics-free enteral formula

Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained

Also known as: Ensure Fos
prebiotics containing enteral formula

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients receiving exclusive EN , nasogastric, continuous infusion
  • Adult patients , 18 years old and above
  • Critically ill patients
  • Expected to require EN more than five days(Bleichner et al., 1997)

You may not qualify if:

  • Patients with gastrointestinal disease (Sokol et al., 2006) or GIT surgery
  • Patients receiving lactulose (Bouhnik et al., 2004)
  • Currently under chemotherapy treatment (Kapkac et al., 2003)
  • Patients who had received prebiotics and probiotics supplements within the previous one month
  • Patients who have diarrhoea, 3 consecutive days (Majid et al, 2013)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Malaya Medical Centre

Petaling Jaya, Kuala Lumpur, 50603, Malaysia

RECRUITING

Related Publications (6)

  • Bleichner G, Blehaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med. 1997 May;23(5):517-23. doi: 10.1007/s001340050367.

    PMID: 9201523BACKGROUND
  • Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Dore J. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006 Feb;12(2):106-11. doi: 10.1097/01.MIB.0000200323.38139.c6.

    PMID: 16432374BACKGROUND
  • Bouhnik Y, Attar A, Joly FA, Riottot M, Dyard F, Flourie B. Lactulose ingestion increases faecal bifidobacterial counts: a randomised double-blind study in healthy humans. Eur J Clin Nutr. 2004 Mar;58(3):462-6. doi: 10.1038/sj.ejcn.1601829.

    PMID: 14985684BACKGROUND
  • Kapkac, M., Erikoglu, M., Tuncyurek, P., Ersin, S., Esassolak, M., Alkanat, M., & Sipahioglu, O. (2003). Fiber enriched diets and radiation induced injury of the gut. Nutrition research (New York, N.Y.), 23(1), 77-83

    BACKGROUND
  • Whelan K, Judd PA, Preedy VR, Taylor MA. Covert assessment of concurrent and construct validity of a chart to characterize fecal output and diarrhea in patients receiving enteral nutrition. JPEN J Parenter Enteral Nutr. 2008 Mar-Apr;32(2):160-8. doi: 10.1177/0148607108314769.

    PMID: 18407909BACKGROUND
  • Majid HA, Cole J, Emery PW, Whelan K. Additional oligofructose/inulin does not increase faecal bifidobacteria in critically ill patients receiving enteral nutrition: a randomised controlled trial. Clin Nutr. 2014 Dec;33(6):966-72. doi: 10.1016/j.clnu.2013.11.008. Epub 2013 Nov 16.

    PMID: 24290345BACKGROUND

MeSH Terms

Conditions

Diarrhea

Interventions

Osmolite

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Mazuin Kamarul Zaman, BSc (RD)

    University of Malaya

    PRINCIPAL INVESTIGATOR
  • Hazreen Abdul Majid, BSc(RD),PhD

    University of Malaya

    PRINCIPAL INVESTIGATOR
  • Vineya Rai Hakumat Rai, MBBS

    University of Malaya

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mazuin Kamarul Zaman

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Mrs

Study Record Dates

First Submitted

May 19, 2014

First Posted

May 21, 2014

Study Start

January 1, 2014

Primary Completion

September 1, 2014

Study Completion

September 1, 2014

Last Updated

May 21, 2014

Record last verified: 2014-05

Locations